| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Expression and Adipocyte DifferentiationHoward Hughes Medical Institute and Department of Pathology and Laboratory Medicine (K.W.P., H.W., C.J.V., C.H., P.T.), University of California, Los Angeles, California 90095; Division of Biological Sciences (L.A.M., A.W.G), University of California, San Diego, La Jolla, California 92093; and Departments of Molecular and Integrative Physiology (S.K., O.M.), University of Michigan Medical Center, Ann Arbor, Michigan 48109-0622
Address all correspondence and requests for reprints to: Peter Tontonoz M.D., Ph.D., Howard Hughes Medical Institute, UCLA School of Medicine, Box 951662, Los Angeles, California 90095-1662. E-mail: ptontonoz{at}mednet.ucla.edu.
| ABSTRACT |
|---|
|
|
|---|
(PPAR
) and adipocyte differentiation. In an effort to identify signaling pathways mediating harmines effects, we performed transcriptional profiling of 3T3-F442A preadipocytes. Inhibitor of DNA biding 2 (Id2) was identified as a gene rapidly induced by harmine but not by PPAR
agonists. Id2 is also induced in 3T3-L1 preadipocytes treated with dexamethasone, 3-isobutyl-1-methylxanthine, and insulin, suggesting that Id2 regulation is a common feature of the adipogenic program. Stable overexpression of Id2 in preadipocytes promotes expression of PPAR
and enhances morphological differentiation and lipid accumulation. Conversely, small interfering RNA-mediated knockdown of Id2 antagonizes adipocyte differentiation. Mice lacking Id2 expression display reduced adiposity, and embryonic fibroblasts derived from these mice exhibit reduced PPAR
expression and a diminished capacity for adipocyte differentiation. Finally, Id2 expression is elevated in adipose tissues of obese mice and humans. These results outline a role for Id2 in the modulation of PPAR
expression and adipogenesis and underscore the utility of adipogenic small molecules as tools to dissect adipocyte biology. | INTRODUCTION |
|---|
|
|
|---|
The nuclear receptor peroxisome proliferator-activated receptor-
(PPAR
) plays a central role in the adipocyte differentiation program. Downstream targets for PPAR
regulation in fat are well characterized. These include numerous genes involved in lipid accumulation and metabolism, such as aP2, CD36, lipoprotein lipase (LPL), perilipin, and phosphoenol pyruvate carboxykinase (1). By contrast, the transcriptional pathways that control expression of PPAR
itself remain incompletely understood. Early studies in cultured cells showed that induction of CCAAT enhancer binding protein (C/EBP)β and C/EBP
facilitates expression of PPAR
(2). Mice lacking C/EBPβ and C/EBP
have a defect in generation of adipose tissues (3). However, PPAR
expression is preserved in fat tissue in these mice, suggesting that additional pathways contribute to PPAR
regulation during adipogenesis.
Consistent with this idea, a number of other transcription factors have also been linked to PPAR
expression. For example, members of the Kruppel-like zinc finger family of transcription factors have been reported to be proadipogenic [KLF5 (4) and KLF15 (5)] or antiadipogenic [KLF2 (6)] modulators of PPAR expression. Other transcription factors linked to the early stages of differentiation include Krox-20 (7), GATA2/3 (8), ternary complex factor (TCF)/Lef (9), E2F (10), and Sma- and Mad-related protein (11). Thus, PPAR
regulation during adipogenesis is complex and requires the integration of multiple transcriptional cascades. It is likely that additional factors contributing to this process remain to be elucidated.
We recently identified the small molecule harmine as an inducer of adipocyte differentiation (12). Remarkably, harmine appears to act by inducing PPAR
mRNA expression in preadipocytes. In the present work, we have used harmine as a tool to probe for transcriptional pathways that trigger PPAR
expression. By profiling the acute effects of harmine on preadipocyte gene expression, we identified Id2 as a mediator of harmine action in adipogenesis.
Id proteins are helix-loop-helix (HLH) domain transcription factors that lack a DNA-binding domain. Ids heterodimerize with other HLH proteins and are involved in a wide range of cellular processes, including development, cell cycle control, differentiation, and tumorigenesis (13). Here we show that ectopic expression of Id2 in preadipocytes promotes PPAR
expression and differentiation, whereas knockdown of Id2 expression is inhibitory. In vivo, Id2 expression is elevated in obese mice and humans. We also show that white adipose tissue (WAT) development is impaired in Id2–/– mice and that Id2–/– mouse embryonic fibroblasts (MEFs) exhibit reduced adipogenic potential. Together, our data demonstrate that Id2 is a transcriptional modifier of PPAR
expression and adipogenesis. These observations shed light on a new factor in adipogenesis and illustrate the utility of adipogenic small molecules as chemical tools to probe fat cell biology.
| RESULTS |
|---|
|
|
|---|
expression (12). To gain insight into the mechanism of action of this novel adipogenic compound, we performed transcriptional profiling analysis of 3T3-F442A cells. We treated 3T3-F442A cells with either harmine or the PPAR
ligand GW7845 for 24 h. As expected, PPAR
target genes including aP2, adiponectin, and phosphoenol pyruvate carboxykinase were up-regulated in cells treated with either harmine or GW7845 (Fig. 1A
would be regulated by harmine but not by GW7845. A limited number of genes, including Id2, Gremlin, Fseg, Rasl11b, and two uncharacterized genes met our criteria of being up-regulated by harmine (>2.5-fold) and not regulated by GW7845 (<1.3-fold change) (Fig. 1A
were up-regulated by harmine but not by GW7845, whereas PPAR
target genes such as aP2 and adiponectin were up-regulated by both treatments (Fig. 1B
expression by harmine is apparent within 4 h (12), we also analyzed the time-dependent regulation of these genes by harmine. Among these genes, Id2 was induced by harmine as rapidly as PPAR
(Fig. 1
, KLF5, and Id2, suggesting that Id2 regulation is a common feature of the adipogenic program (Fig. 1D
|
Expression and Adipocyte Differentiation
expression, we transiently overexpressed either Id2 or PPAR
in 3T3-L1 preadipocytes. Transient overexpression of Id2 increased PPAR
expression (Fig. 1F
did not alter expression of Id2 (Fig. 1F
induction in these studies was modest, it was highly reproducible in multiple experiments (data not shown) and was consistent with the 2- to 3-fold up-regulation observed with harmine. This observation suggests that Id2 is upstream of PPAR
in the differentiation cascade (see below).
Based on the ability of Id2 to induce PPAR
expression after short-term transient expression, we asked whether Id2 promotes adipocyte differentiation. To test this possibility, we used a retroviral vector to generate preadipocytes stably expressing Id2. Consistent with the transient transfection results, stable expression of Id2 in 3T3-L1 cells increased expression of PPAR
at confluence (Fig. 2A
). After stimulation of differentiation with adipogenic reagents, 3T3-L1 cells stably expressing Id2 displayed increased expression of PPAR
and its target genes aP2, CD36, LPL, adiponectin, and C/EBP
(Fig. 2
, A and B). Moreover, Id2-expressing cells showed increased capacity for morphological differentiation and lipid accumulation as determined by Oil red O staining (Fig. 2C
). Importantly, promotion of adipocyte differentiation by Id2 was also observed in other preadipocytes cell lines, including C3H10T1/2 (Fig. 2C
), 3T3-F442A, and M2–10B cells (data not shown). These data identify Id2 as a novel adipogenic transcription factor that induces PPAR
expression.
|
expression and inhibited adipocyte differentiation of 3T3-F442A and 3T3-L1 cells (Fig. 3A
expression by harmine (Fig. 3B
|
expression (12). As expected, 6-methoxyharman was also the only derivative besides harmine capable of inducing Id2 (Fig. 3D
To further establish the role of Wnt signaling in the regulation of Id2 and PPAR
expression by harmine, we generated stable 3T3-F442A cells expressing a dominant-negative form of TCF (dnTCF). This dominant-negative construct was previously shown to reduce Wnt-stimulated gene expression and activity. Induction of Id2 expression by harmine in dnTCF cells was significantly blunted compared with controls (Fig. 3E
). Together, these data demonstrate that the regulation of Id2 by harmine results, at least in part, from inhibition of the Wnt signaling pathway.
Id2 Acts Upstream of PPAR
in Adipogenesis
Enforced expression of Id2 in 3T3-L1 cells increased expression of PPAR
, suggesting that Id2 acts upstream of PPAR
in the adipogenic cascade. To further validate this hypothesis, we generated stable 3T3-F442A cells expressing short hairpin RNA (shRNA) against PPAR
. Two independent shRNA constructs targeting different regions of the PPAR
mRNA were used. Both shRNAs effectively reduced PPAR
mRNA expression (Fig. 4A
) and protein levels (Fig. 4B
). As expected, 3T3-F442A cells expressing PPAR
shRNA showed markedly reduced differentiation and lipid accumulation (data not shown). Expression of downstream target genes of PPAR
, including aP2, adiponectin, and CD36, was markedly reduced in PPAR
shRNA-expressing cells, both in the presence and absence of harmine (Fig. 4D
). By contrast, expression of Id2 was not affected by knockdown of PPAR
, demonstrating that Id2 is indeed upstream of PPAR
(Fig. 4C
).
|
(Fig. 5B
, aP2, and adiponectin expression by DMI and harmine during adipogenesis (Fig. 5D
expression and adipocyte differentiation.
|
|
Loss of Id2 Expression Affects WAT Development in Mice
Id2 is widely expressed in vivo, including in brown and white adipose tissues (data not shown). To address the potential impact of Id2 deletion on WAT development in vivo, we analyzed Id2 null mice. Both mouse and human models have established that loss of PPAR
causes lipodystrophy (15, 16). Thus, it is likely that genes regulating PPAR
expression may also affect adipocyte development in vivo. As previously reported, the gross phenotype of Id2–/– mice at birth was indistinguishable from that of wild-type littermates on the C57BL/6 background (17). However, by d 6, Id2–/– neonates were noticeably runted despite the ability to suckle, and these mice did not survive beyond 2 wk of age. Cross-sections of 6-d-old neonates followed by hematoxylin and eosin staining showed reduced WAT development in Id2–/– pups compared with Id2+/+ controls (Fig. 7A
). Dissection at d 4 revealed that neonatal mutant mice exhibited relative deficiencies in interscapular and inguinal fat pads (Fig. 6B
and data not shown). Despite this difference in WAT mass, size and morphology of adipocytes and liver were not significantly different (data not shown). These data strongly suggest that Id2 may play a modulatory role in adipocyte development in vivo.
|
2, LPL, adiponectin, and aP2 mRNA were reduced in hormone-induced Id2–/– MEFs compared with Id2+/+ MEFs (Fig. 7D
were not altered in Id2–/– cells. Together, these data demonstrate that Id2 is a modifier of adipocyte differentiation in vitro and in vivo. | DISCUSSION |
|---|
|
|
|---|
expression and inhibition of the Wnt signaling pathway. In the present work, we have used harmine as a chemical tool to identify the transcription factor Id2 as a new player in the adipocyte differentiation program.
By profiling gene expression in preadipocytes treated acutely with harmine, we identified Id2 as a harmine-responsive gene. We showed that expression of Id2 is induced not only by harmine, but also by the classic adipogenic DMI cocktail, suggesting that induction of Id2 is a common feature of the differentiation program. The rapid and transient induction of Id2 by DMI treatment is reminiscent of other early adipogenic PPAR
regulators such as CEBPβ and KLF5. Retroviral expression of Id2 stimulates PPAR
expression and promotes morphological differentiation in multiple preadipocyte cell lines. Furthermore, inhibition of Id2 expression with siRNA approaches inhibited the differentiation of 3T3-L1 cells and blunted the expression of PPAR
and its downstream target genes. Id2 expression is positively correlated with body mass in genetic and diet-induced obese mice. Interestingly, elevated expression of Id2 is also observed in human obese populations. Finally, impaired WAT development in Id2–/– mice and adipocyte differentiation of Id2–/– MEFs are consistent with a role for Id2 in adipose development.
Harmine stimulates differentiation through induction of PPAR
expression and inhibition of the Wnt signaling pathway. Precisely how these effects are accomplished on a molecular level, however, is unknown. In this study, we also explored the connection between harmine, Id2, PPAR
and the Wnt signaling pathway during adipocyte differentiation. First, we determined that Id2 acts downstream of Wnt. Treatment of preadipocytes with Wnt-conditioned medium and purified Wnt-3a inhibited the expression of Id2 and PPAR
(Fig. 3
and data not shown). We also showed that the ability of harmine to induce Id2 and PPAR
was reduced in cells expressing dnTCFs. Second, we established that Id2 acts upstream of PPAR
in the differentiation cascade. Transient and stable expression of Id2 induced PPAR
expression in preadipocytes. Whereas shRNA-mediated knockdown of PPAR
abolished the ability of harmine to stimulate differentiation, Id2 induction by harmine was still detectable. These data suggest that Id2 acts upstream of PPAR
during adipogenesis.
Nevertheless, given the fact that adipogenic effects were not completely blunted in Id2 siRNA transfected cells (Fig. 5D
), the possibility that Id2 is not the only mediator of harmine action in adipogenesis must be considered. As we have identified other harmine-responsive genes (Fig. 1
), future studies to address the function of these proteins may help to reveal additional adipogenic mechanisms of harmine.
Identification of Id2 as a PPAR
modulator promoted us to test whether Id2 modulates expression and activity of C/EBPs, known PPAR
regulators. Gain and loss of function of Id2 did not alter levels and activity of early adipogenic PPAR
regulators (C/EBPβ and C/EBP
) (Figs. 5
and 7
, and data not shown). Conversely, overexpression of C/EBP
did not change the Id2 expression whereas it induced PPAR
expression (data not shown). These data suggest that Id2 and C/EBPβ/
do not act similar in pathways in adipogenic cascades. In fact, the Id proteins lacking DNA-binding domains are believed to function by inhibiting the action of other transcription factors. Previous studies have shown that Ids interact with basic HLH, adipocyte determination and differentiation factor 1/sterol regulatory element-binding protein-1c (18), Ets transcription factor (19), retinoblastoma (20), and E-proteins (21). Several of these factors have been linked to adipogenesis, including adipocyte determination and differentiation factor 1/sterol regulatory element-binding protein-1c and retinoblastoma protein (22, 23). Currently, the cis- and trans-acting factors with which Id2 interacts to stimulate PPAR
expression remain to be established. Of note, Id3 has been previously reported to inhibit adipocyte differentiation (18) in contrast to our observations with Id2. We did not observe changes in Id3 expression in response to the adipogenic compound harmine. Accordingly, different Id family members may have different functions in this cell type. Interestingly, recent work from Seidman and colleagues (24) identified Id2 as a key factor in the development of the cardiac conduction system. Thus, our results fit well with the hypothesis that Id2 serves as an important factor in the development of several specialized cell types.
Id2 is ubiquitously expressed, suggesting multiple functions in many types of cells. Id2–/– mice were previously reported to have defects in epithelial proliferation in mammary glands, lacking lymph nodes and Peyers patches, and reduced population of natural killer cells and Langerhans cells (25). Additional data further showed that Id2 is critical in CD8+ T cell immunity and cardiac development (17, 24). Here we have documented reduced WAT development in Id2–/– mice. Clearly, the reduced adiposity of Id2–/– mice could be secondary to alterations in other tissues and cell types. However, our observation that Id2–/– MEFs show reduced capacity for adipocyte differentiation are consistent with intrinsic defects in adipose tissue in the absence of Id2. Future studies, likely involving tissue-specific knockout mice, will be required to dissect potential roles for Id2 in obesity, insulin resistance, and systemic metabolism.
| MATERIALS AND METHODS |
|---|
|
|
|---|
knockdown were previously described (26).
Cell Culture
3T3-L1 and 3T3-F442A preadipocyte cell lines were maintained and differentiated as previously described (12). M2 mouse mesenchymal stem cells were purchased from American Type Culture Collection. M2 cells were maintained in growth medium consisting of RPMI 1640 with 10% fetal bovine serum and supplemented with 1 mM sodium pyruvate, 100 U/ml penicillin, and 100 U/ml streptomycin. Retroviral overexpression of Id2 was performed using pBabe-puro and the packaging cell line Phoenix E as described elsewhere (27). siRNAs from Dharmacon were resuspended according to the manufacturers instructions. Id2 siRNAs were transfected using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA). A concentration of 10 nM siRNA was transfected into 50% confluent 3T3-L1 cells. After 48 h, media were changed and processed further as differentiation protocols. MEFs were isolated from E13.5 Id2+/+ and Id2–/– embryos. MEFs were differentiated in dexamethasone (1 µM), IBMX (0.5 mM), and insulin (5 µg/ml) for 2 d after confluence, followed by insulin alone.
RNA and Protein Analysis
Total RNA was isolated using TRIzol reagent (Invitrogen). Total RNA (0.5 µg) was reverse transcribed using MultiScribe (Applied Biosystems, Foster City, CA) and random hexamers according to the manufacturers instructions. Real-time quantitative PCR (SYBR green) analysis was performed on a 7900HT Fast Real-Time PCR System (Applied Biosystems). Expression was normalized to 36B4. The following primers were used for Ids expression:
ID1 forward (ID1F), 5'-gcgagatcagtgccttgg-3'; and ID1R reverse (ID1R), 5'-ctcctgaagggctggagtc-3'; ID2 forward (ID2F), 5'-ggaccacagcttgggcat-3'; ID2 reverse (ID2R), 5'-cgttcatgttgtagagcagactcat-3'; ID3 forward (ID3F), 5'-gaggagcttttgccactgac-3'; ID3 reverse (ID3R), 5'-gagagagggtcccagagtcc-3'; ID4 forward (ID4F); agggtgacagcattctctgc; ID4 reverse (ID4R); ccggtggcttgtttctctta.
Protein preparation, SDS-PAGE, and Western blotting were performed as previously described (12). Antiserum against murine PPAR
(sc-7196) and actin were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Animals
C57BL/6 wild-type mice, C57BL/6 ob/ob, and C57BLKS/J-Lepr db/db mice were purchased from The Jackson Laboratory (Bar Harbor, ME). For relative gene expression studies in diet-induced obesity, wild-type male (C57BL/6) mice were fed either with regular chow or high-fat diet (60% fat) for 11 months. For genetic induced obesity, 13-wk-old male C57BL/6J ob/ob and wild-type C57BL/6 male mice were used. Id2 knockout mice were generated, maintained as previously described (17). Id2–/– pups were generated by mating heterozygote (+/–), and littermates were used as controls for each experiment. The animal studies were approved by the Institutional Animal Care and Use Committee of University of California, Los Angeles (UCLA) and conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals.
Microarrays
Total RNA from 24 h harmine-treated F442A cells prepared using TRIzol and further purified using RNAeasy columns (QIAGEN, Chatsworth, CA). cDNA preparation and hybridization to Affymetrix Mouse Genome Arrays 430 version 2.0 were performed by UCLA Microarray. Core and data were analyzed using GeneSpring GX 7.3 (Agilent Technologies, Palo Alto, CA).
| ACKNOWLEDGMENTS |
|---|
H.W. is a Fellow and P.T. is an Investigator of the Howard Hughes Medical Institute at UCLA.
| FOOTNOTES |
|---|
First Published Online June 18, 2008
1 K.W.P. and H.W. contributed equally to this work. ![]()
Abbreviations: BMI, Body mass index; C/EBP, CCAAT enhancer binding protein; DMI, dexamethasone, IBMX, and insulin; dnTCF, dominant-negative TCF; E13.5, embryonic d 13.5; HLH, helix-loop-helix; IBMX, 3-isobutyl-1-methylxanthine; Id 2, inhibitor of DNA binding; KLF, Kruppel-like factor; LPL, lipoprotein lipase; MEFs, mouse embryonic fibroblasts; PPAR, peroxisome proliferator-activated receptor; shRNA, short hairpin RNA; siRNA, small interfering RNA; TCF, ternary complex factor; WAT, white adipose tissue.
Received for publication October 3, 2007. Accepted for publication June 11, 2008.
| REFERENCES |
|---|
|
|
|---|
and stimulates adipogenesis. Genes Dev 9:2350–2363
gene. EMBO J 16:7432–7443[CrossRef][Medline]
expression and adipogenesis. J Biol Chem 278:2581–2584
and steroidogenic factor 1 transcription factors. Mol Cell Biol 23:5366–5375
expression. Cell Metab 5:357–370[CrossRef][Medline]
associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880–883[CrossRef][Medline]
(PPAR
) mutant is a constitutive repressor and inhibits PPAR
-mediated adipogenesis. J Biol Chem 275:5754–5759
and peroxisome proliferator-activated receptor
. J Biol Chem 282:14515–14524
2, a lipid-activated transcription factor. Cell 79:1147–1156[CrossRef][Medline]NURSA Molecule Pages Link:
This article has been cited by other articles:
![]() |
L. A. Monticelli, Y. Yang, J. Knell, L. M. D'Cruz, M. A. Cannarile, I. Engel, M. Kronenberg, and A. W. Goldrath Transcriptional regulator Id2 controls survival of hepatic NKT cells PNAS, November 17, 2009; 106(46): 19461 - 19466. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhang, C. Paddon, M. D Lewis, F. Grennan-Jones, and M. Ludgate Gs{alpha} signalling suppresses PPAR{gamma}2 generation and inhibits 3T3L1 adipogenesis J. Endocrinol., August 1, 2009; 202(2): 207 - 215. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Hausman, M. V. Dodson, K. Ajuwon, M. Azain, K. M. Barnes, L. L. Guan, Z. Jiang, S. P. Poulos, R. D. Sainz, S. Smith, et al. BOARD-INVITED REVIEW: The biology and regulation of preadipocytes and adipocytes in meat animals J Anim Sci, April 1, 2009; 87(4): 1218 - 1246. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |